Beijing He Yan Ling Pharmaceutical Development

Beijing He Yan Ling Pharmaceutical Development is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of recombinant protein therapeutics for medical aesthetics and dermatology. The company's core focus is the creation of next-generation botulinum toxin products using proprietary recombinant technology, which offers advantages in purity and consistency over traditional animal-derived methods. Its lead candidate, HYL-001, is a recombinant botulinum toxin type A currently in Phase 2 clinical trials for the treatment of glabellar lines. Beyond aesthetics, the company is exploring therapeutic applications for its protein platform in areas such as hyperhidrosis and neuromuscular disorders. Backed by prominent investors like Sequoia China, He Yan Ling aims to become a leader in the high-growth Chinese medical aesthetics market.